ATX Share Price Performance
AU$0.17
0.02 (10.00%)
Price AU$0.17
Share PriceAU$0.17
Amplia Therapeutics Limited Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
ATX Community Narratives
There are no narratives available yet.
Recent ATX News & Updates
Amplia Therapeutics Limited Key Details
Last Reported Earnings
Mar 31, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.013
- Gross Margin
- 94.43%
- Net Profit Margin
- -173.69%
- Debt/Equity Ratio
- 0%
Amplia Therapeutics Limited Competitors
Snowflake Analysis
About ATX
- Founded
- 2000
- Employees
- n/a
- CEO
- WebsiteView website
Amplia Therapeutics Limited, a clinical-stage drug development company, engages in the development of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. Its product pipeline comprises Narmafotinib (AMP945), an inhibitor of FAK, which is in 1b/2a clinical trial for pancreatic cancer; and treatment of idiopathic pulmonary fibrosis, as well as ovarian cancer. It also develops AMP886 for application in oncology and chronic fibrosis indications. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.
Market Insight
Rare earths may be a sliver of the global metals market, but they punch far above their weight. These obscure elements are the invisible wiring of modern life.
Continue reading
Australian Market Performance
- 7 Days: 2.3%
- 3 Months: 5.3%
- 1 Year: 10.1%
- Year to Date: 9.7%
Over the last 7 days, the market has risen 2.3%, driven by gains of 2.9% in the Financials sector. In the last year, the market has climbed 10%. Earnings are forecast to grow by 11% annually. Market details ›